Brazilian Diabetes Prevention Program for Prediabetes

Inclusion Criteria * Be 18 years or older (no maximum age for being eligible) * Have a body mass index (BMI) between 18,5 and 34,9kg/m² * Have, at least, one electronic device (includes any of the following devices): * Computer * Laptop/notebook * Tablet * Smartphone * Have access to internet (broadband, 3G, 4G, 5G, among others) Without previous nutritional counseling (within the 6 months prior to recruitment/randomization/intervention) Without supervision by a Physical Education Professional (Personal Trainer) in the past 6 months * Living near the research center (at maximum 60 minutes) * Diagnosis of prediabetes defined as two HbA1c measurements between 5.7% and 6.4% collected 7 to 90 days apart. Exclusion Criteria: * Diagnosis of Diabetes Mellitus (including current or recent use, within three months, of glucose-lowering medication) * Underlying disease likely to limit life expectancy and/or increase the risk of interventions influencing the risk of developing T2D * Diagnosis of Renal Disease * Diagnosis of Pulmonary Disease * Gastrointestinal Disease * Secondary prevention for Cardiovascular Disease * Endocrine Diseases * Weight loss exceeding 10% in the last 6 months (except postpartum-related) * Uncontrolled Hypertension * Diagnosis of Polycystic Ovary Syndrome (self-reported) * Patients undergoing treatment for Tuberculosis (except those using isoniazid \[INH\] as prophylaxis) * Presence of diseases that may severely reduce life expectancy or the ability to participate in the study * Pregnant or breastfeeding women * Severe psychiatric disorders that, in the opinion of the clinical team, hinder participation in the program * Acute or chronic excessive alcohol consumption * Congestive Heart Failure (CHF) with a New York Heart Association Functional Class (NYHA) \> 2 * Need for referral to a cardiologist according to the Physical Activity Readiness Questionnaire (PAR-Q) * Current or recent participation (within the last six months) in another clinical trial that impacts the interventions and/or is associated with the study outcomes (in case of doubt, contact the coordinating center) * Likely relocation away from the research collaborating center within the next 3 years * Another household member is a participant or a team member of the PROVEN-DIA study * Unwillingness to accept treatment assignment by randomization and/or refusal to participate in the study (signing the Informed Consent Form) * Continuous use of the following medications: Corticosteroids other than topical, ophthalmic, or inhaled preparations Antineoplastic agents Psychoactive agents Other medications. • Participant from the pilot Randomized Clinical Trial (Brazilian Diabetes Prevention Program: Pilot Study (PROVEN-Dia), NCT05689658)